Submit Your Feeds

Business News • PR NewsWire • ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole

ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole

LEUVEN, Belgium, June 12, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has...

View More : http://www.prnewswire.com/news-releases/thrombogenics-jetrea-receives-positive-initial-nice-recommendation-for-vitreomac...
Releted News by prnewswire
Leading Companies Team Up to Develop an Unrivalled Lithium Sulfur Solar Energy Storage System
Almost Half the UK Listens to Audio/Radio Online Each Week, Finds New Audiometrics Survey
ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
Home Sitemap Contact Us
© businessNewsNewsNews.com